Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

USA - NASDAQ:SRPT - US8036071004 - Common Stock

17.44 USD
-0.1 (-0.57%)
Last: 11/18/2025, 8:00:01 PM
17.61 USD
+0.17 (+0.97%)
After Hours: 11/18/2025, 8:00:01 PM
Fundamental Rating

3

Overall SRPT gets a fundamental rating of 3 out of 10. We evaluated SRPT against 533 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRPT had negative earnings in the past year.
SRPT had a negative operating cash flow in the past year.
SRPT had negative earnings in 4 of the past 5 years.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

SRPT has a better Return On Assets (-7.77%) than 86.12% of its industry peers.
Looking at the Return On Equity, with a value of -20.57%, SRPT belongs to the top of the industry, outperforming 83.30% of the companies in the same industry.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SRPT has a better Gross Margin (76.25%) than 84.05% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
Compared to 5 years ago, SRPT has more shares outstanding
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of -0.13. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
SRPT has a Altman-Z score of -0.13. This is in the better half of the industry: SRPT outperforms 61.35% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a worse Debt to Equity ratio (0.78) than 74.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC7.28%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
With a Current ratio value of 2.95, SRPT is not doing good in the industry: 63.60% of the companies in the same industry are doing better.
A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
SRPT has a worse Quick ratio (1.79) than 77.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
Measured over the past years, SRPT shows a very strong growth in Revenue. The Revenue has been growing by 37.94% on average per year.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%

3.2 Future

SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.24% yearly.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.07% yearly.
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 7.20 indicates a rather cheap valuation of SRPT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 98.69% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.98, SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.2
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.1%
EPS Next 3Y2.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (11/18/2025, 8:00:01 PM)

After market: 17.61 +0.17 (+0.97%)

17.44

-0.1 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners81.76%
Inst Owner Change2%
Ins Owners4.63%
Ins Owner Change11.82%
Market Cap1.83B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68
Price Target33.01 (89.28%)
Short Float %17.35%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)0.25%
PT rev (3m)3.87%
EPS NQ rev (1m)-18.71%
EPS NQ rev (3m)-46.58%
EPS NY rev (1m)1.99%
EPS NY rev (3m)-5.44%
Revenue NQ rev (1m)5.06%
Revenue NQ rev (3m)7.97%
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)6.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.2
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)2.42
Fwd EY13.9%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS23.06
BVpS12.61
TBVpS12.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z -0.13
F-Score3
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRPT.


What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.


How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.


What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?

The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -292.84% in the next year.